Showing 2441-2450 of 2656 results for "".
- James Mazzo Joins Board of Directors at Avellino Labshttps://modernod.com/news/james-mazzo-joins-board-of-directors-at-avellino-labs/2476451/Avellino Labs announced the strategic addition of James V. Mazzo to its board of directors. The partnership will further anchor Avellino Lab’s leadership in developing the science and setting the standard of genetic testing in ophthalmology, according to a company news release.
- Arkansas Secures Expanded Scope of Practicehttps://modernod.com/news/arkansas-secures-expanded-scope-of-practice/2479581/As advocates nationwide work to advance optometry’s future-focused role in health care, Arkansas becomes the latest state enacting scope of practice expansion to include surgical procedures, according to the American Optometric Association. Signed into law March 27 by Gov. Asa Hutch
- 5% People Tested Positive at Free Initial Screenings for Glaucoma at Saifee Hospitalhttps://modernod.com/news/5-people-tested-positive-at-free-initial-screenings-for-glaucoma-at-saifee-hospital/2476400/Saifee Hospital, one of Mumbai’s leading multi-specialty hospitals, conducted almost 400 free eye check-ups for their visitors to observe World Glaucoma Week. The check-ups were conducted throughout the week and more than 20 people were detected to have high
- Study Demonstrates Long-Term IOP Reduction with the OMNI Surgical System Predicate Device (TRAB 360) in MIGShttps://modernod.com/news/clinical-study-demonstrates-long-term-iop-reduction-with-the-omni-surgical-system-predicate-device-trab-360-in-migs/2476378/A new, single-center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI Surgical System’s Predicate Devices (TRAB 360)
- Survey: Physicians Generate an Average of $2.4 Million a Year Per Hospitalhttps://modernod.com/news/survey-physicians-generate-an-average-of-2-4-million-a-year-per-hospital/2479591/While physicians are key providers of medical care at the nation’s hospitals, a new survey confirms they also are major drivers of hospital revenue. According to the survey, physicians generate an average $2,378,727 per year in net revenue on behalf of their af
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- Neurotech Pharmaceuticals Granted Fast Track Designation from the FDA for the Treatment of Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-fda-for-the-treatment-of-macular-telangiectasia-type-2/2476300/Neurotech Pharmaceuticals announced that the FDA has granted Fast Track designation for the company’s development candidate, NT-501 or Renexus, for the treatment of macular telangiectasia type 2 (MacTel). Fast track is a designation by the FDA to facilitate the development and expedite the
- ARISE-3 Phase 3 Clinical Trial of the RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTreehttps://modernod.com/news/arise-3-phase-3-clinical-trial-of-the-rgn-259-for-the-treatment-of-dry-eye-syndrome-is-initiated-by-regentree/2476304/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it has executed an agreement with Ora for the initiation of ARISE-3 to study the company’s new drug RGN-259 for the treatment of dry eye syndrome. ARISE-3 is a randomized, double masked, placebo cont
- Statement From FDA Leadership On a Record Year for Device Innovationhttps://modernod.com/news/statement-from-fda-leadership-on-a-record-year-for-device-innovation/2479598/FDA Commissioner Scott Gottlieb, MD, and Jeff Shuren, MD, director for the Center for Devices and Radiological Health, released the following statement addressing a record year for device innovation: “The FDA’s focus on both safety and innovation stems from our historic mission
- Burnout Rises Above 50% in Some Specialties, New Survey Showshttps://modernod.com/news/burnout-rises-above-50-in-some-specialties-new-survey-shows/2476179/Responses to a new Medscape survey indicate that 44% of physicians meet the criteria for burnout, up from 42% in last year’s report. In addition, 11% are colloquially depressed (feeling down or sad), and 4% are clinically depressed, according to the